Association of Serum Autotaxin Levels with Liver Fibrosis in Patients with Chronic Hepatitis C-Reference-Cited by-同舟云学术

Association of Serum Autotaxin Levels with Liver Fibrosis in Patients with Chronic Hepatitis C

Published:2017-04-20 Issue:1 Volume:7 Page:
ISSN:2045-2322
Container-title:Scientific Reports
language:en
Short-container-title:Sci Rep

Author:

Yamazaki Tomoo,Joshita Satoru,Umemura Takeji,Usami Yoko,Sugiura Ayumi,Fujimori Naoyuki,Shibata Soichiro,Ichikawa Yuki,Komatsu Michiharu,Matsumoto Akihiro,Igarashi Koji,Tanaka Eiji

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/srep46705.pdf

Reference39 articles.

1. Kiyosawa, K. et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology (Baltimore, Md.) 12, 671–675, doi: S0270913990002361 [pii] (1990).

2. Gane, E. J. et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 368, 34–44, doi: 10.1056/NEJMoa1208953 (2013).

3. Poordad, F. et al. Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med 368, 45–53, doi: 10.1056/NEJMoa1208809 (2013).

4. Kumada, H. et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology (Baltimore, Md.) 59, 2083–2091, doi: 10.1002/hep.27113 (2014).

5. Mizokami, M. et al. Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial. The Lancet. Infectious diseases 15, 645–653, doi: 10.1016/s1473-3099(15)70099-x (2015).

Cited by 52 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The enigma of sickle cell hepatopathy: Pathophysiology, clinical manifestations and therapy;British Journal of Haematology;2024-07-08

2. Sodium/bile acid co-transporter inhibitors currently in preclinical or early clinical development for the treatment of primary biliary cholangitis;Expert Opinion on Investigational Drugs;2024-04-24

3. Serum autotaxin is a prognostic indicator of liver-related events in patients with non-alcoholic fatty liver disease;Communications Medicine;2024-04-16

4. Value of autotaxin for hepatocellular carcinoma risk assessment in chronic hepatitis B patients treated with nucleos(t)ide analogs;Hepatology Research;2024-03-27

5. Autotaxin is a potential predictive marker for the development of veno-occlusive disease/sinusoidal obstruction syndrome after allogeneic hematopoietic cell transplantation;Annals of Hematology;2024-03-18